Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.63 |
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365483 | 0.84 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2085894 | 0.84 | ALDH1A1 (0.64) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13733750 | 0.84 | PTGS1 (0.48) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3541254 | 0.81 | KDM4E (0.60) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14704055 | 0.81 | ALDH1A1 (0.62) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL21001618 | 0.81 | EGLN1 (0.57) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL12393079 | 0.80 | PTGS1 (0.44) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28695262 | 0.79 | KDM4E (0.67) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29479625 | 0.79 | KDM4E (0.67) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13733069 | 0.79 | PTGS1 (0.49) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113439084-B | Sesqui-carcinomycin analogue | 奥克兰联合服务有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3704120-B1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11459338-B2 | Heterocyclic compounds as PRMT5 inhibitors | JUBILANT EPISCRIBE LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220098215-A1 | DUOCARMYCIN ANALOGUES | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-03-31 | — | — | US | disclosed |
| EP-3917933-A1 | DUOCARMYCIN ANALOGUES | Auckland Uniservices Limited (NZ) | 2021-12-08 | — | — | EP | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| CN-113439084-A | Duocarmycin analogs | 奥克兰联合服务有限公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-111542523-A | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2020-08-14 | — | — | CN | disclosed |
| WO-2020157662-A1 | DUOCARMYCIN ANALOGUES | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157662-A1 | DUOCARMYCIN ANALOGUES | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-08-06 | — | — | WO | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
| EP-2041133-B1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-10-13 | — | — | EP | disclosed |
| EP-2041133-A1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003856-A1 | DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098215-A1 | DUOCARMYCIN ANALOGUES | TOP2A, TOP2B, MUS81 | NPC1 3762/4885RAB9A 3146/4885SMN1; SMN2 1555/4885 |
| US-11459338-B2 | Heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | NPC1 3585/4885RAB9A 462/4885SMN1; SMN2 972/4885 |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | NPC1 3585/4885RAB9A 462/4885SMN1; SMN2 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.